Guardant Health Inc. announces a multi-year strategic partnership with biopharmaceutical company Nuvalent

Both parties will leverage Guardant Health's Guardant Infinity™ liquid biopsy platform to jointly develop innovative companion diagnostic solutions, providing commercial support for Nuvalent’s targeted cancer therapies. This collaboration will focus on advancing precision medicine, accelerating Nuvalent’s clinical development of tumor-targeted drugs with Guardant Health’s advanced liquid biopsy technology. The Guardant Infinity™ platform enables comprehensive genomic analysis through blood samples, delivering critical data support for personalized treatment plans.This strategic partnership covers full-cycle support from drug development to commercialization, marking a new stage in the application of liquid biopsy technology for precision cancer treatment. Both sides will integrate their professional strengths in diagnostic technology and drug development, working together to provide cancer patients with more precise and efficient treatment solutions.